Innoviva (INVA) EBIT Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Innoviva | 1.60 Bn | 992.84 Mn | 75.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 55.25% |
| Dec 31, 2025 | -16.46% |
| Sep 30, 2025 | -16.35% |
| Jun 30, 2025 | -8.45% |
| Mar 31, 2025 | -11.45% |
| Dec 31, 2024 | -16.47% |
| Sep 30, 2024 | -6.59% |
| Jun 30, 2024 | -1.76% |
| Mar 31, 2024 | -17.04% |
| Dec 31, 2023 | -15.83% |
| Sep 30, 2023 | 8.31% |
| Jun 30, 2023 | -16.58% |
| Mar 31, 2023 | -17.91% |
| Dec 31, 2022 | -16.60% |
| Sep 30, 2022 | -83.43% |
| Jun 30, 2022 | -17.00% |
| Mar 31, 2022 | -18.12% |
| Dec 31, 2021 | -16.66% |
| Sep 30, 2021 | 27.63% |
| Jun 30, 2021 | 30.12% |
| Mar 31, 2021 | -18.23% |
| Dec 31, 2020 | -18.87% |
| Sep 30, 2020 | 58.52% |
| Jun 30, 2020 | 71.50% |
| Mar 31, 2020 | 152.27% |
| Dec 31, 2019 | 255.33% |
| Sep 30, 2019 | 52.95% |
| Jun 30, 2019 | 51.96% |
| Mar 31, 2019 | 40.85% |
| Dec 31, 2018 | 65.49% |
| Sep 30, 2018 | 56.81% |
| Jun 30, 2018 | 61.79% |
| Mar 31, 2018 | 26.34% |
| Dec 31, 2017 | 29.03% |
| Sep 30, 2017 | 26.19% |
| Jun 30, 2017 | 27.27% |
| Mar 31, 2017 | -19.36% |
| Dec 31, 2016 | 25.06% |
| Sep 30, 2016 | 24.21% |
| Jun 30, 2016 | 25.34% |
| Mar 31, 2016 | 23.07% |
| Dec 31, 2015 | 24.28% |
| Sep 30, 2015 | 19.38% |
| Jun 30, 2015 | 17.74% |